Междисциплинарный подход к проблеме желчнокаменной болезни у женщин: взгляд гинеколога

1. Strom BL, Tamragouri RN, Morse ML et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39: 335–41.
2. Бурков С. Г. О последствиях холецистэктомии или постхолецистэктомическом синдроме. Гастроэнтерология (Прил. к журн. Consilium Medicum). 2004; 6 (2): 24–7.
 [Burkov S. G. O posledstviiakh kholetsistektomii ili postkholetsistektomicheskom sindrome. Gastroenterology (Suppl. Consilium Medicum). 2004; 6 (2): 24–7 (in Russian).]
3. Бурков С. Г., Гребенев А. Л. Желчнокаменная болезнь (эпидемиология, патогенез, клиника). Руководство по гастроэнтерологии. В трех томах. Под общей ред. Ф. И. Комарова, А. Л. Гребенева. Т. 2. Болезни печени и билиарной системы. М.: Медицина, 1995;
с. 417–41.
 [Burkov S. G., Grebenev A. L. Gallstone disease (epidemiology, pathogenesis, clinic). Guide to gastroenterology. In three volumes. Ed. F.I. Komarova, A.L. Grebeneva. V. 2. Diseases of the liver and biliary system. Moscow: Meditsina, 1995; s. 417–41 (in Russian).]
4. Вихрова Т.В. Билиарный сладж и его клиническое значение. Дис. канд. мед. наук. М., 2003.
 [Vikhrova T.V. Biliarnyi sladzh i ego klinicheskoe znachenie. Dis. kand. med. nauk. Moscow, 2003 (in Russian).]
5. Григорьева И.Н., Романова Т.И. Основные факторы риска и качество жизни у больных желчнокаменной болезнью. Эксперим. и клин. гастроэнтерология. 2011; 4: 21–5.
 [Grigor'eva I.N., Romanova T.I. Osnovnye faktory riska i kachestvo zhizni u bol'nykh zhelchnokamennoi bolezn'iu. Eksperim. i klin. gastroenterologiia. 2011; 4: 21–5 (in Russian).]
6. Лазебник Л. Б., Копанева М. И., Ежова Т. Б. Потребность в медицинской помощи после оперативных вмешательств на желудке и желчном пузыре (обзор литературы и собственные данные).  Терапевтический архив. 2004; 2: 83–7.
 [Lazebnik L.B., Kopaneva, I.M., Ezhova T. B. Need for medical care after surgery on the stomach and gall blad-der (Review of references and own observations). Therapeutic Archive. 2004; 2: 83–7. (in Russian).]
7. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J 2001; 77: 221–9.
8. Koebnick C, Smith N, Black MH et al. Pediatric obesity and gallstone disease. J Pediatr Gastroenterol Nutr 2012; 55 (3): 328–33. DOI: 10.1097/MPG.0b013e31824d256f
9. European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65 (1): 146–81. DOI: 10.1016/j.jhep.2016.03.005
10. Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Lancet 1973; 1: 1399–404.
11.  Cirillo DJ, Wallace RB, Rodabough RJ et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005; 293: 330–9.
12. De Bari O, Wang TY, Liu M et al. Cholesterol cholelithiasis in pregnant women: pathogenesis, prevention and treatment. Ann Hepatol 2014; 13 (6): 728–45.
13. Maringhini A, Ciambra M, Baccelliere P et al. Biliary sludge and gallstones in pregnancy: incidence, risk factors, and natural history. Ann Intern Med 1993; 119: 116–20.
14. Honore LH. Increased incidence of symptomatic cholesterol cholelithiasis in perimenopausal women receiving estro- gen replacement therapy: a retrospective study. J Reprod Med 1980; 25: 187–90.
15. Attili AF, De Santis A, Capri R et al. The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology 1995; 21: 655–60.
16. Лейшнер У. Практическое руководство по заболеваниям желчных путей. М.: ГЭОТАР-Мед, 2001.
 [Leishner U. A Practical Guide to Biliary Diseases. Moscow: GEOTAR-Med, 2001. (in Russian).]
17. Ильченко А.А. Желчнокаменная болезнь. М.: Анахарсис, 2004.
 [Il'chenko A.A. Cholelithiasis. Moscow: Anakharsis, 2004 (in Russian).]
18. Caruso MG, Giangrande M, Clemente C et al. Lipidi sierici e sabbia biliare durante la gravidanza [Serum lipids and biliary sludge during pregnancy]. Minerva Gastroenterol Dietol 1993; 39 (2): 67–70.
19. Duan LP, Wang HH, Ohashi A, Wang DQ. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol 2006; 290 (2): G269–G276. DOI: 10.1152/ajpgi.00172.2005
20. Liu B, Beral V, Balkwill A et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337: a386. DOI: 10.1136/bmj.a386
21. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005; 7: 132–40.
22. Ko CW, Beresford SA, Schulte SJ et al. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005; 41: 359–65.
23. Philipp BW, Shapiro DJ. Estrogen regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and acetyl-CoA carboxylase in xenopus laevis. J Biol Chem 1981; 256 (6): 2922–7.
24. Руководство по репродуктивной медицине. Под ред. Б. Карра,
Р. Блэкуэлла, Р. Азиза. Пер. с англ. М.: Практика, 2015.
 [Reproductive Medicine Guide. Pod red. B. Karra, R. Blekuella,
R. Aziza. Per. s angl. Moscow: Praktika, 2015 (in Russian).]
25. El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 109: 239–41.
26. Valdivieso V, Covarrubias C, Siegel F, Cruz F. Pregnancy and cholelithiasis: pathogenesis and natural course of gallstones diagnosed in early puerperium. Hepatology 1993; 17: 1–4.
27. Ness GC, Chambers CM. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000; 224 (1): 8–19.
28. Isik S, Ozcan HN, Ozuguz U et al. Impaired gallbladder motility and the effect of metformin therapy in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 76 (3): 373–8. DOI: 10.1111/j.1365-2265.2011.04210.x.
29. Kline LW, Karpinski E. Testosterone and dihydrotestosterone inhibit gallbladder motility through multiple signaling pathways. Steroids 2008; 73: 1174–80.
30. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65 (2): 137–45.
31. Иванченкова Р.А. Хронические заболевания желчевыводящих путей. М.: Атмосфера, 2006.
 [Ivanchenkova R.A. Chronic diseases of the biliary tract. Moscow: Atmosfera, 2006 (in Russian).]
32. Sieron D, Czerny B, Sieron-Stoltny K et al. The effect of chronic estrogen application on bile and gallstone composition in women with cholelithiasis. Minerva Endocrinol 2016; 41 (1): 19–27.
33. Racine A, Bijon A, Fournier A et al. Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. CMAJ 2013; 185 (7): 555–61. DOI: 10.1503/cmaj.121490
34. Wild RA. The PCO paradigm: sex steroids, lipoprotein lipids, clotting, and the arterial wall. In The Ovary: Regulation, Dysfunction and Treatment. M Filicori and C Flamigni, eds. Elsevier Science B.V., 1996;
p. 201–9.

________________________________________________

1. Strom BL, Tamragouri RN, Morse ML et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39: 335–41.
2. Burkov S. G. O posledstviiakh kholetsistektomii ili postkholetsistektomicheskom sindrome. Gastroenterology (Suppl. Consilium Medicum). 2004; 6 (2): 24–7 (in Russian).
3. Burkov S. G., Grebenev A. L. Gallstone disease (epidemiology, pathogenesis, clinic). Guide to gastroenterology. In three volumes. Ed. F.I. Komarova, A.L. Grebeneva. V. 2. Diseases of the liver and biliary system. Moscow: Meditsina, 1995; s. 417–41 (in Russian).
4. Vikhrova T.V. Biliarnyi sladzh i ego klinicheskoe znachenie. Dis. kand. med. nauk. Moscow, 2003 (in Russian).
5. Grigor'eva I.N., Romanova T.I. Osnovnye faktory riska i kachestvo zhizni u bol'nykh zhelchnokamennoi bolezn'iu. Eksperim. i klin. gastroenterologiia. 2011; 4: 21–5 (in Russian).
6. Lazebnik L.B., Kopaneva, I.M., Ezhova T. B. Need for medical care after surgery on the stomach and gall blad-der (Review of references and own observations). Therapeutic Archive. 2004; 2: 83–7. (in Russian).
7. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J 2001; 77: 221–9.
8. Koebnick C, Smith N, Black MH et al. Pediatric obesity and gallstone disease. J Pediatr Gastroenterol Nutr 2012; 55 (3): 328–33. DOI: 10.1097/MPG.0b013e31824d256f
9. European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65 (1): 146–81. DOI: 10.1016/j.jhep.2016.03.005
10. Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Lancet 1973; 1: 1399–404.
11.  Cirillo DJ, Wallace RB, Rodabough RJ et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005; 293: 330–9.
12. De Bari O, Wang TY, Liu M et al. Cholesterol cholelithiasis in pregnant women: pathogenesis, prevention and treatment. Ann Hepatol 2014; 13 (6): 728–45.
13. Maringhini A, Ciambra M, Baccelliere P et al. Biliary sludge and gallstones in pregnancy: incidence, risk factors, and natural history. Ann Intern Med 1993; 119: 116–20.
14. Honore LH. Increased incidence of symptomatic cholesterol cholelithiasis in perimenopausal women receiving estro- gen replacement therapy: a retrospective study. J Reprod Med 1980; 25: 187–90.
15. Attili AF, De Santis A, Capri R et al. The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology 1995; 21: 655–60.
16. Leishner U. A Practical Guide to Biliary Diseases. Moscow: GEOTAR-Med, 2001. (in Russian).
17. Il'chenko A.A. Cholelithiasis. Moscow: Anakharsis, 2004 (in Russian).
18. Caruso MG, Giangrande M, Clemente C et al. Lipidi sierici e sabbia biliare durante la gravidanza [Serum lipids and biliary sludge during pregnancy]. Minerva Gastroenterol Dietol 1993; 39 (2): 67–70.
19. Duan LP, Wang HH, Ohashi A, Wang DQ. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol 2006; 290 (2): G269–G276. DOI: 10.1152/ajpgi.00172.2005
20. Liu B, Beral V, Balkwill A et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337: a386. DOI: 10.1136/bmj.a386
21. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005; 7: 132–40.
22. Ko CW, Beresford SA, Schulte SJ et al. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005; 41: 359–65.
23. Philipp BW, Shapiro DJ. Estrogen regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and acetyl-CoA carboxylase in xenopus laevis. J Biol Chem 1981; 256 (6): 2922–7.
24. Reproductive Medicine Guide. Pod red. B. Karra, R. Blekuella, R. Aziza. Per. s angl. Moscow: Praktika, 2015 (in Russian).
25. El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 109: 239–41.
26. Valdivieso V, Covarrubias C, Siegel F, Cruz F. Pregnancy and cholelithiasis: pathogenesis and natural course of gallstones diagnosed in early puerperium. Hepatology 1993; 17: 1–4.
27. Ness GC, Chambers CM. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000; 224 (1): 8–19.
28. Isik S, Ozcan HN, Ozuguz U et al. Impaired gallbladder motility and the effect of metformin therapy in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 76 (3): 373–8. DOI: 10.1111/j.1365-2265.2011.04210.x.
29. Kline LW, Karpinski E. Testosterone and dihydrotestosterone inhibit gallbladder motility through multiple signaling pathways. Steroids 2008; 73: 1174–80.
30. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65 (2): 137–45.
31. Ivanchenkova R.A. Chronic diseases of the biliary tract. Moscow: Atmosfera, 2006 (in Russian).
32. Sieron D, Czerny B, Sieron-Stoltny K et al. The effect of chronic estrogen application on bile and gallstone composition in women with cholelithiasis. Minerva Endocrinol 2016; 41 (1): 19–27.
33. Racine A, Bijon A, Fournier A et al. Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. CMAJ 2013; 185 (7): 555–61. DOI: 10.1503/cmaj.121490
34. Wild RA. The PCO paradigm: sex steroids, lipoprotein lipids, clotting, and the arterial wall. In The Ovary: Regulation, Dysfunction and Treatment. M Filicori and C Flamigni, eds. Elsevier Science B.V., 1996;
p. 201–9.

Ю.Б. Успенская*1, И.В. Кузнецова2, А.А. Шептулин3

1 Клиника «Андреевские больницы – НЕБОЛИТ», Москва, Россия;
2 НОЧУ ДПО «Высшая медицинская школа», Москва, Россия;
3 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*jusp@mail.ru

________________________________________________

Yulia B. Uspenskaya*1, Irina V. Kuznetsova2, Arkadiy A. Sheptulin3

1 Andreevsky hospitals – NEBOLIT, Moscow, Russia;
2 Higher Medical School, Moscow, Russia;
3 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*jusp@mail.ru